IP Library Granted Patent US 7,750,187
Granted Patent B2
US 7,750,187 · App. 11/719,001 · Granted Jul 6, 2010

Crystallization method for benzphetamine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,750,187
App. No.
11/719,001
Granted
Jul 6, 2010
Kind
B2
Abstract

There is disclosed a method for the crystallization of benzphetamine hydrochloride from an organic medium by the steps of removing water from the system to a very low level and then reducing the temperature of the organic medium to provide crystallization of the acid salt. In the event that crystallization does not occur upon lowering the temperature of the medium, it has been discovered that gentle heating of the organic medium results in crystallization of the acid salt. It has also been discovered that higher temperature crystallization has been provided by removal of methamphetamine from the composition. The crystalline benzphetamine hydrochloride can then be isolated by typical liquid/solid separation means such as filtration or centrifugation.

Claims (45)

1. A process for preparing a crystalline form of benzphetamine hydrochloride comprising:

(a) dispersing a crude benzphetamine hydrochloride in an organic medium in which benzphetamine hydrochloride is essentially insoluble to form a biphasic mixture comprising the crude benzphetamine hydrochloride and the organic medium, the biphasic mixture containing an amount of water;

(b) contacting the biphasic mixture with a drying agent to remove water from the crude benzphetamine hydrochloride and to lower the water content of the biphasic mixture to less than about 0.11% by weight;

(c) crystallizing the benzphetamine hydrochloride product from (b); and

(d) separating the crystalline benzphetamine hydrochloride from the organic medium.

2. The process of claim 1 wherein the organic medium is selected from the group consisting of xylene, toluene, ethyl acetate, heptane, cyclohexane and benzene.

3. The process of claim 2 wherein the organic medium is toluene.

4. The process of claim 1 wherein the organic medium is a reaction medium in which the crude benzphetamine hydrochloride is produced.

5. The process of claim 1 wherein crystallizing the benzphetamine hydrochloride comprises cooling the biphasic mixture through the temperature range of from about 60° C. to about 40° C.

6. The process of claim 1 wherein crystallizing the benzphetamine hydrochloride comprises cooling the biphasic mixture through the temperature range of from about 60° C. to about 40° C. and then heating the biphasic mixture to a temperature above about 40° C.

7. The process of claim 6 wherein the biphasic mixture is heated to a temperature between about 40° C. to about 100° C.

8. The process of claim 1 wherein crystallizing the benzphetamine hydrochloride comprises heating the biphasic mixture to a temperature between about 40° C. and about 100° C.

9. The process of claim 8 wherein crystallizing the benzphetamine hydrochloride further comprises cooling the biphasic mixture to precipitate the crystalline benzphetamine hydrochloride.

10. The process of claim 1 wherein the crystalline benzphetamine hydrochloride is separated from the organic medium by filtration.

11. The process of claim 1 wherein the drying agent is selected from the group consisting of zeolites, magnesium sulfate and calcium chloride.

12. The process of claim 1 wherein the water content of the biphasic mixture is lowered to less than about 0.09%.

13. The process of claim 1 wherein the water content of the biphasic mixture is lowered to less than about 0.02%.

14. The process of claim 1 wherein the crude benzphetamine hydrochloride contains methamphetamine, and further wherein the crystalline benzphetamine hydrochloride contains less methamphetamine than the crude benzphetamine hydrochloride.

15. The process of claim 14 wherein the benzphetamine hydrochloride crystallizes at a temperature in the range of from about 70° C. to about 95° C.

16. A process for preparing a crystalline form of benzphetamine hydrochloride comprising:

(a) dispersing a crude benzphetamine hydrochloride in an organic medium in which benzphetamine hydrochloride is essentially insoluble to form a biphasic mixture comprising the crude benzphetamine hydrochloride and the organic medium, the biphasic mixture containing an amount of water;

(b) removing water from the biphasic mixture by use of a drying agent or by azeotropic distillation of the organic medium;

(c) removing up to about 80%, by volume, of the organic medium by distillation;

(d) adding fresh organic medium to the mixture;

(e) crystallizing the benzphetamine hydrochloride product from (d); and

(f) isolating the crystalline benzphetamine hydrochloride by means of solid\liquid separation.

17. The process of claim 16 wherein the organic medium is toluene.

18. The process of claim 16 wherein the organic medium is ethyl acetate.

19. The process of claim 16 wherein the organic medium is the reaction medium in which the crude benzphetamine hydrochloride is produced.

20. The process of claim 16 wherein the solid\liquid separation is by means of filtration.

21. The process of claim 16 wherein the solid\liquid separation is by means of centrifugation.

22. The process of claim 18 wherein the solid\liquid separation is by means of vacuum filtration.

23. The process of claim 16 wherein step (d) further comprises distilling the fresh organic medium from the mixture.

24. A process for preparing a crystalline form of benzphetamine hydrochloride comprising:

(a) dispersing a crude benzphetamine hydrochloride in an organic medium in which benzphetamine hydrochloride is essentially insoluble to form a biphasic mixture comprising the crude benzphetamine hydrochloride and the organic medium, the biphasic mixture containing an amount of water;

(b) removing water from the crude benzphetamine hydrochloride in the biphasic mixture by azeotropic distillation of the organic medium to lower the water content of the biphasic mixture to less than about 0.11% by weight;

(c) crystallizing the benzphetamine hydrochloride product from (b); and

(d) separating the crystalline benzphetamine hydrochloride from the organic medium.

25. The process of claim 24 wherein the organic medium is selected from the group consisting of xylene, toluene, ethyl acetate, heptane, cyclohexane and benzene.

26. The process of claim 25 wherein the organic medium is toluene.

27. The process of claim 24 wherein the organic medium is a reaction medium in which the crude benzphetamine hydrochloride is produced.

28. The process of claim 24 wherein crystallizing the benzphetamine hydrochloride comprises cooling the biphasic mixture through the temperature range of from about 60° C. to about 40° C. and then heating the biphasic mixture to a temperature above about 40° C.

29. The process of claim 24 wherein crystallizing the benzphetamine hydrochloride comprises heating the biphasic mixture to a temperature between about 40° C. and about 100° C. and cooling the biphasic mixture to precipitate the crystalline benzphetamine hydrochloride.

30. The process of claim 24 wherein the water content of the biphasic mixture is lowered to less than about 0.09%.

31. The process of claim 24 wherein the water content of the biphasic mixture is lowered to less than about 0.02%.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2007
From: KALOTA, DENNIS J.; TOMAZI, KEITH G.
To: MALLINCKRODT INC.
Reel/Frame 019338/0993 →